Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention

Abstract

Objective:

We aimed to investigate the compliance of plasma apelin-12 levels to show angiographic properties and hospital MACE in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).

Material and Methods:

The association of apelin-12 levels with the N/L ratio on admission was assessed in 170 consecutive patients with primary STEMI undergoing primary PCI. All patient SYNTAX scores and thrombolysis in myocardial infarction (TIMI) flow grades were also assessed. Patients were divided into two groups according to their TIMI flow grade. Patients with a TIMI 0-2 flow and TIMI 3 flow with grade 0/1 myocardial blush grade (MBG) score were defined as the no-reflow group and patients with TIMI grade 3 flow with ⩾2 MBG were considered as the normal flow group.

Results:

Baseline apelin-12 levels were significantly lower in the no-reflow group than in the normal flow group (3.3±1.81 vs 6.2±1.74, p<0.001). In-hospital events, including death, myocardial infarction (MI) and re-infarction were significantly higher in patients in the no-reflow group than normal flow group (23% vs 7%, p<0.001). Apelin-12 level was negative correlated with the N/L ratio (r= -0.352, p<0.001), Hs-Crp (r=-0.272, p=0.01) and SYNTAX score (r= -0.246, p=0.029). In the multivariate regression analysis, apelin-12, presence of no-reflow and the SYNTAX score were independent predictors of in-hospital MACE (odds ratio [OR] 1.41, 95% confidence interval (CI) [1.27 to 1.67], p=0.001 for apelin-12, OR 1.085, [0.981 to 1.203], p<0.001 for no-reflow and OR 0.201, 95% CI [0.05 to 0.47], p= 0.004 for SYNTAX score).

Conclusion:

We have shown that lower apelin-12 level on admission is associated with higher SYNTAX scores and no-reflow phenomenon and may be used as a prognostic marker for hospital MACE in patients with STEMI.

Keywords

STEMI apelin-12 SYNTAX score TIMI flow grade score no-reflow

Get full access to this article

View all access options for this article.

References

Zahorec

. Ratio of neutrophil to lymphocyte counts–rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 1: 5–14.

Núñez

Bodí

. Usefulness of the neutrophil to lymphocyte ratio in predicting long-term mortality in ST segment elevation myocardial infarction. Am J Cardiol 2008; 101: 747–752.

Boucher

Masri

Daviaud

. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764–1771.

Sonmez

Celebi

Erdem

. Plasma apelin and ADMA levels in patients with essential hypertension. Clinical and Experimental Hypertension 2010; 32: 179–183.

Leal

Lobo

Stockler-Pinto

. Apelin: a peptide involved in cardiovascular risk in hemodialysis patients? Ren Fail 2012; 34: 577–581.

Lakomkin

Tereshchenko

Sychev

. Biomarkers in heart failure: apelin level is not associated with presence and severity of the disease. Kardiologiia 2015; 2: 37–41.

Boal

Roumegoux

Alfarano

. Apelin regulates FoxO3 translocation to mediate cardioprotective responses to myocardial injury and obesity. Sci Rep. 2015; 5: 16104.

Dalzell

Rocchiccioli

Weir

. The emerging potential of the apelin-APJ system in heart failure. J Card Fail. 2015; 21: 489–498.

TIMI Study Group. The Thrombolysis In Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 1985; 14: 932–936.

10.

Niccoli

Lanza

Spaziani

. Baseline systemic inflammatory status and noreflow phenomenon after percutaneous coronary angioplasty for acute myocardial infarction. Int J Cardiol 2007; 117: 306–311.

11.

Sianos

Morel

Kappetein

. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention 2005; 1: 219–227.

12.

Leaman

Brower

Meester

Serruys

van den Brand

. Coronary artery atherosclerosis: severity of the disease, severity of angina pectoris and compromised left ventricular function. Circulation 1981; 63: 285–299.

13.

Liu

Hai-Tao

Chen

Mai

Jin

. Serum apelin level predicts the major adverse cardiac events in patients With ST elevation myocardial infarction receiving percutaneous coronary intervention. Medicine. 2015; 94: e449

14.

Herrmann

. Peri-procedural myocardial injury: 2005 update. Eur Heart J 2005; 26: 2493–2519.

15.

Chun

Ali

Kojima

. Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest 2008; 118: 3343–3354.

16.

Boucher

Masri

Daviaud

. Apelin, a newly identified adipokine up-regulated by insulin and obesity. Endocrinology 2005; 146: 1764–1771.

17.

Valgimigli

Serruys

Tsuchida

. Cyphering the complexity of coronary artery disease using the syntax score to predict clinical outcome in patients with three-vessel lumen obstruction undergoing percutaneous coronary intervention. Am J Cardiol 2007; 99: 1072–1081.

18.

Gibson

Cannon

Murphy

. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125–130.

19.

Gregorini

Marco

Farah

. Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting. Circulation 2002; 106: 2901–2907.

20.

Salcedo

Garijo

Monge

. Apelin effects in human splanchnic arteries: role of nitric oxide and prostanoids. Regul Pept 2007; 144: 50–55.

21.

Japp

Cruden

Amer

DAB

. Vascular effects of apelin in vivo in man. J Am Coll Cardiol 2008; 52: 908–913.

22.

Lloyd-Jones

Bloch

. The vascular biology of nitric oxide and its role in atherogenesis. Ann Rev Med 1996; 47: 365–375.

23.

Laskin

Heck

Lakin

. Multifunctional role of nitric oxide in inflammation. Trends Endocrinol Metab 1994; 5: 377– 382.

24.

Traverse

Kinn

Klassen

Duncker

Bache

. Nitric oxide inhibition impairs blood flow during exercise in hearts with a collateral-dependent myocardial region. J Am Coll Cardiol 1997; 31: 67–74.

25.

Hillegass

Dean

Liao

Rhinehart

Myers

. Treatment of no-reflow and impaired flow with the nitric oxide donor nitroprusside following percutaneous coronary interventions: initial human clinical experience. J Am Coll Cardiol 2001; 37: 1335– 1343.

26.

Reilly

Delanty

Roy

. Increased formation of the isoprostanes IPF2alpha-I and 8-epi-prostaglandin F2 alpha in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 1997; 96: 3314 –3320.

27.

Iuliano

Praticò

Greco

. Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. J Am Coll Cardiol 2001; 37: 76–80.

28.

Zeng

Zhang

Wang

Tang

. Apelin protects heart against ischemia/reperfusion injury in rat. Peptides 2009; 30: 1144–1152.

29.

Libby

Ridker

Maseri

. Inflammation and atherosclerosis. Circulation 2002; 9: 1135–1143.

30.

Duffy

Gurm

Rajagopal

Gupta

Ellis

Bhatt

. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol 2006; 97: 993–996.

31.

Nakachi

Kosuge

Hibi

. C-reactive protein elevation and rapid angiographic progression of nonculprit lesion in patients with non-ST-segment elevation acute coronary syndrome. Circ J 2008; 72: 1953–1959.

32.

Szokodi

Tavi

Foldes

. Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 2002; 91: 434–440.

33.

Maioli

Zeymer

van’t Hof

AWJ

. EGYPT Cooperation. Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors. J Invasive Cardiol 2012; 24: 324–327.